D&B Business Directory
Elusys Therapeutics, Inc.
Overview
Elusys
Elusys Therapeutics is recruiting antibodies in its anti-terrorism campaign. The company develops antibody therapies for a variety of targets, including anthrax. Its lead product Anthim was approved by the US FDA in 2016 to treat and prevent inhaled anthrax; Elusys received federal funding for its research efforts on the drug. The company has partnered with Pfizer on another drug development program targeting S taphylococcus aureus ...
Read More
(staph) infections, which have become increasingly prevalent and resistant to treatment. Elusys antibodies have potential applications in the treatment of additional infectious agents.
Read Less
Elizabeth Posillico   See more contacts
?
?
Actual

?
Actual
#
Modelled
? ?
Contacts
Get in Touch with 4 Principals* and 10 Contacts
  • Elizabeth Posillico
    President and Chief Executive Officer
  • Contact 2
    ?
  • Contact 3
    ?
  • Contact 4
    ?
D&B Hoovers Logo

Dynamic search and list-building capabilities

Real-time trigger alerts

Comprehensive company profiles

Valuable research and technology reports

Financial Data
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Stay on top of your Business Credit File
Get full access to view your D&B business credit file now for just $39/month!
View D&B Scores & Ratings